title: Therapeutic efficacy of interferon alfa-2b in infants with life-threatening giant hemangiomas.
abstract: BACKGROUND
  Because of their size and the possibility of complications, giant hemangiomas represent a therapeutic challenge. Various forms of treatment have been used, with variable results, including surgery, embolization, lasers, pentoxifylline, and corticosteroids. Interferon alfa has been used successfully to treat life-threatening hemangiomas, possibly by means of its antiangiogenic activity.
  
  
  METHODS
  We treated 7 infants with organ-interfering and/or life-threatening giant hemangiomas with subcutaneous injections of 3 million U/m2 per day of interferon alfa-2b during the first month and subsequently every 48 to 72 hours, depending on the evolution in each case. The treatment lasted from 3 to 12 months. In 2 patients, interferon alfa-2b was administered while prednisone therapy was being tapered. In all 7 patients, there was considerable reduction of the volume of the hemangiomas and remission of their complications. All patients presented with fever, neutropenia, and an increase in serum aminotransferase levels. The patients who received interferon alfa-2b and prednisone seemed to improve at a faster rate.
  
  
  CONCLUSIONS
  Interferon alfa-2b is a good option for the treatment of patients with steroid-resistant, organ-interfering and/or life-threatening giant hemangiomas. In our experience, the adverse effects were transient and minor and did not require the interruption of the treatment.
authors.affiliation: Department of Dermatology, National Institute of Pediatrics, Mexico City, Mexico.
authors.forename: L
authors.initials: L
authors.lastname: Tamayo
authors.forename: D M
authors.initials: DM
authors.lastname: Ortiz
authors.forename: L
authors.initials: L
authors.lastname: Orozco-Covarrubias
authors.forename: C
authors.initials: C
authors.lastname: Durán-McKinster
authors.forename: M A
authors.initials: MA
authors.lastname: Mora
authors.forename: E
authors.initials: E
authors.lastname: Avila
authors.forename: F
authors.initials: F
authors.lastname: Teixeira
authors.forename: R
authors.initials: R
authors.lastname: Ruiz-Maldonado
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004341:Drug Evaluation; D005142:Eyelid Neoplasms / Q000175:diagnosis / Q000628:therapy*; D005153:Facial Neoplasms / Q000175:diagnosis / Q000628:therapy*; D005260:Female; D006258:Head and Neck Neoplasms / Q000175:diagnosis / Q000628:therapy*; D006391:Hemangioma / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D007223:Infant; D007279:Injections, Subcutaneous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D011446:Prospective Studies; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000175:diagnosis / Q000628:therapy*; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins